Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5522)	1/22/2002 4:16:48 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 52153

Peter: This is the third CNS program in the past few years (off the top of my head) I have seen run into Phase II immunoreactivity issues after passing Phase I satisfactorily. NeuroSearch's NS2710 anxiolytic and Neurocrine's APL for MS both had trials suspended in 1999 due to possible immune reactions, skin rashes in both cases. Both programs were dumped by their partners (Pharmacia and Novartis respectively), and have yet to resume Phase II, almost three years later, even though neither company believes the drug to be at fault. It is hard to prove the negative, unless they find some smoking gun viral culprit. What I am hearing fits your second scenario, that the desired autoimmune reaction--in some people at some doses--in itself is accompanied by inflammation. And if you cannot parse the two, AN-1792 would be doomed. Harry Tracy NeuroInvestment www.neuroinvestment.com